In this week’s View, Dr. Eagle discusses a comparison of patients infected with Delta versus Omicron COVID-19 variants, then looks at a post-hoc analysis of the EMPEROR-Preserved trial on mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. Finally, Dr. Eagle explores a recent NCDR Registry paper on sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock.

Clinical Topics: Cardiovascular Care Team, COVID-19 Hub, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Stable Ischemic Heart Disease, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Interventions and Coronary Artery Disease, Interventions and Imaging, Interventions and Vascular Medicine, Angiography, Nuclear Imaging, Hypertension, Chronic Angina

Keywords: EaglesEyeView, C-Reactive Protein, SARS-CoV-2, COVID-19, Renal Insufficiency, Chronic, Dyspnea, Hypertension, Vaccination, Diabetes Mellitus, Natriuretic Peptide, Brain, Mineralocorticoid Receptor Antagonists, Sodium Potassium Chloride Symporter Inhibitors, Heart Failure, Heart Failure, Blood Pressure, Hyperkalemia, Ventricular Function, Left, Cardiomyopathies, Coronary Artery Disease, Shock, Cardiogenic, Hospital Mortality, ST Elevation Myocardial Infarction, Sex Characteristics, Non-ST Elevated Myocardial Infarction, Percutaneous Coronary Intervention, Myocardial Infarction, Angiography, Renal Dialysis

< Back to Listings